RMD - ResMed Inc.
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. (“ResMed” or the “Company”) (NYSE: RMD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Turning 73 changes the math on your retirement account. The IRS no longer lets your traditional IRA compound in peace.
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lead Director on November 15, 2026. She will succeed Ron Taylor, Resmed's current Lead Director, who is not standing for reelection at the company's 2026 Annual Meeting of Stockholders on November 18, 2026, and will retire after more than 21 years of service to the company.
Avalon Trust Co bought a new stake in ResMed Inc. (NYSE: RMD) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 87,722 shares of the medical equipment provider's stock, valued at approximately $17,095,000. ResMed makes up 1.1% of Avalon
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
ResMed NYSE: RMD reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share rose 16% to $2.95, while the company expanded gross margin despite continued inflation in electronic components and freight.
Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.
Shares of ResMed dropped about 6% in morning trade on Friday after the medtech company forecast fiscal 2027 revenue below Wall Street expectations, impacted by suspended ventilator sales and cost pressures.
Revenue: Group revenue for Q4 FY2026 was $1.5 billion, a 9% headline increase and 8% growth on a constant currency basis.Non-GAAP Earnings Per Share: Increased
ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript
ResMed (RMD) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.9 per share. This compares to earnings of $2.55 per share a year ago.
Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95 Returned $1.0 billion to shareholders through share repurchases and dividends during FY2026, an increase of more than 70% Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2026.
Globus Medical and Resmed enter the earnings season with growth drivers intact despite tariff, inflation and hospital spending pressures.
Evaluate the expected performance of ResMed (RMD) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
RMD's Q4 results may reflect strong mask and device demand, portfolio innovation, acquisitions and digital health growth, with EPS seen rising 13.7%.
BankChampaign National Association acquired a new stake in shares of ResMed Inc. (NYSE: RMD) during the first quarter, according to its most recent filing with the SEC. The fund acquired 2,981 shares of the medical equipment provider's stock, valued at approximately $669,000. Several other institutional investors and hedge funds have also bought and
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
American Capital Management Inc. cut its stake in ResMed Inc. (NYSE: RMD) by 13.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 265,399 shares of the medical equipment provider's stock after selling 41,557 shares during the period. ResMed
TROY, Mich., July 21, 2026 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Broadridge Financial Resources Inc. (NYSE: BR) as its "Stock to Study" and ResMed Inc. (NYSE: RMD) as its "Undervalued Stock" in the October 2026 issue for investors' informational and educational use.